Miguel Haime1, Robert R McLean2,3,4, Katherine E Kurgansky4, Maximilian Y Emmert5, Nicole Kosik4, Constance Nelson4, Michael J Gaziano1,4,6, Kelly Cho1,4,6, David R Gagnon6,7. 1. a VA Boston Healthcare System , Harvard Medical School , West Roxbury , MA , USA. 2. b Hebrew SeniorLife , Institute for Aging Research , Roslindale , MA , USA. 3. c Department of Medicine , Beth Israel Deaconess Medical Center and Harvard Medical School , Boston , MA , USA. 4. d Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) , VA Boston Healthcare System , Boston , MA , USA. 5. e Clinic for Cardiovascular Surgery , University Hospital of Zurich , Zurich , Switzerland. 6. f Division of Aging , Brigham and Women's Hospital , Boston , MA , USA. 7. g Department of Biostatistics , Boston University School of Public Health , Boston , MA , USA.
Abstract
BACKGROUND: Saphenous vein grafts (SVGs) remain the most often used conduits for coronary bypass grafting (CABG). Progressive intimal hyperplasia contributes to vein-graft disease and vein-graft failure (VGF). We compared the impact of intraoperative preservation of SVGs in a storage solution (DuraGraft®) versus heparinized saline on VGF-related outcomes after CABG. METHODS: From 1996 to 2004, 2436 patients underwent isolated CABG with ≥ 1 SVG. SVGs were consecutively treated with DuraGraft in 1036 patients (2001-2004) and heparinized saline in 1400 patients (1996-1999). Short- (< 30 days) and long-term (≥ 1000 days) outcomes were assessed using repeat revascularization (primary end point), and major adverse cardiac events (MACE) consisting of the composite of death, nonfatal myocardial infarction, or repeat revascularization. RESULTS: Mean follow-up in the DuraGraft group was 8.5 ± 4.2 years and 9.9 ± 5.6 years in controls. Short-term event rates were low and generally did not differ between groups. DuraGraft was associated with a 45% lower occurrence of nonfatal myocardial infarction after 1000 days (hazard ratio 0.55, 95% CI 0.41-0.74; P < 0.0001). There was 35% and 19% lower long-term risk for revascularization (HR 0.65, 95% CI 0.44-0.97; P = 0.037) and MACE (HR 0.81, 95% CI 0.70-0.94; P = 0.0051), respectively, after DuraGraft. Mortality was comparable between both groups at 1, 5, and 10 years. There was no statistically significant association between DuraGraft exposure and time to death starting at 30 or 1000 days (HR 0.91, 95% CI 0.76-1.09; P = 0.29). CONCLUSION: In this study, intraoperative treatment of SVGs with DuraGraft was associated with a lower risk of long-term adverse events suggesting that efficient intraoperative SVG treatment may reduce VGF-related complications post-CABG. These data warrant randomized clinical trials to validate these findings.
BACKGROUND: Saphenous vein grafts (SVGs) remain the most often used conduits for coronary bypass grafting (CABG). Progressive intimal hyperplasia contributes to vein-graft disease and vein-graft failure (VGF). We compared the impact of intraoperative preservation of SVGs in a storage solution (DuraGraft®) versus heparinized saline on VGF-related outcomes after CABG. METHODS: From 1996 to 2004, 2436 patients underwent isolated CABG with ≥ 1 SVG. SVGs were consecutively treated with DuraGraft in 1036 patients (2001-2004) and heparinized saline in 1400 patients (1996-1999). Short- (< 30 days) and long-term (≥ 1000 days) outcomes were assessed using repeat revascularization (primary end point), and major adverse cardiac events (MACE) consisting of the composite of death, nonfatal myocardial infarction, or repeat revascularization. RESULTS: Mean follow-up in the DuraGraft group was 8.5 ± 4.2 years and 9.9 ± 5.6 years in controls. Short-term event rates were low and generally did not differ between groups. DuraGraft was associated with a 45% lower occurrence of nonfatal myocardial infarction after 1000 days (hazard ratio 0.55, 95% CI 0.41-0.74; P < 0.0001). There was 35% and 19% lower long-term risk for revascularization (HR 0.65, 95% CI 0.44-0.97; P = 0.037) and MACE (HR 0.81, 95% CI 0.70-0.94; P = 0.0051), respectively, after DuraGraft. Mortality was comparable between both groups at 1, 5, and 10 years. There was no statistically significant association between DuraGraft exposure and time to death starting at 30 or 1000 days (HR 0.91, 95% CI 0.76-1.09; P = 0.29). CONCLUSION: In this study, intraoperative treatment of SVGs with DuraGraft was associated with a lower risk of long-term adverse events suggesting that efficient intraoperative SVG treatment may reduce VGF-related complications post-CABG. These data warrant randomized clinical trials to validate these findings.
Authors: Mehmet H Kural; Yuling Li; Juan Wang; Kaleb M Naegeli; Emmanuelle A Hugentobler; Laura E Niklason Journal: Circ Res Date: 2022-06-23 Impact factor: 23.213
Authors: Etem Caliskan; Domingos Ramos de Souza; Andreas Böning; Oliver J Liakopoulos; Yeong-Hoon Choi; John Pepper; C Michael Gibson; Louis P Perrault; Randall K Wolf; Ki-Bong Kim; Maximilian Y Emmert Journal: Nat Rev Cardiol Date: 2019-08-27 Impact factor: 32.419
Authors: Etem Caliskan; Sigrid Sandner; Martin Misfeld; Jose Aramendi; Sacha P Salzberg; Yeong-Hoon Choi; Vilas Satishchandran; Geeta Iyer; Louis P Perrault; Andreas Böning; Maximilian Y Emmert Journal: J Cardiothorac Surg Date: 2019-10-15 Impact factor: 1.637
Authors: Gábor Veres; Kálmán Benke; Roland Stengl; Yang Bai; Klára Aliz Stark; Alex Ali Sayour; Tamás Radovits; Sivakkanan Loganathan; Sevil Korkmaz-Icöz; Matthias Karck; Gábor Szabó Journal: Antioxidants (Basel) Date: 2022-01-18
Authors: Philipp Szalkiewicz; Maximilian Y Emmert; Paul P Heinisch; Zsuzsanna Arnold; Ingo Crailsheim; Markus Mach; Thomas Aschacher; Martin Grabenwöger; Bernhard Winkler Journal: Front Cardiovasc Med Date: 2022-07-28